European journal of gastroenterology & hepatology
-
Eur J Gastroenterol Hepatol · Oct 2013
Multicenter Study Observational StudyAssociation between thrombocytosis and iron deficiency anemia in inflammatory bowel disease.
Thrombocytosis and iron deficiency anemia are frequent complications of inflammatory bowel disease (IBD). The aim of this study was to investigate the correlation between iron deficiency anemia and thrombocytosis in IBD patients. ⋯ The absolute PLT count seems to correlate with iron deficiency anemia parameters and disease activity in IBD patients. Controlling the inflammation and managing iron deficiency could lead to reversal of thrombocytosis in IBD patients.
-
Eur J Gastroenterol Hepatol · Oct 2013
Case ReportsInterleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis.
Neonatal-onset inflammatory bowel disease (IBD) accounts for only 0.25% of pediatric IBD cases. The molecular pathogenesis of IBD remains unclear. Recently, rare Mendelian mutations have been identified in children with very early-onset Crohn's disease and ulcerative colitis. ⋯ She underwent fistulectomy and ileostomy, but experienced frequent relapses. Mutations, c.[272A>G];[301C>T] (p.[Y91C];[R101W]), were found in IL-10RA. This report confirms the genetic defect of IL-10RA in neonatal-onset IBD including 'intractable ulcerating enterocolitis in infancy'.
-
Eur J Gastroenterol Hepatol · Oct 2013
Clinical TrialPeginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
The hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients treated with peginterferon-α2a (peg-IFN α2a) is still low (about 30%). The aim of this study was to find a new combination therapy of peg-IFN α2a with lamivudine to improve the efficacy in HBeAg-positive chronic hepatitis B patients. ⋯ This study indicates that the response-guided approach resulted in an overall HBeAg seroconversion rate of 47% at EOT and 44% 24 weeks after treatment. This promising strategy to increase response rates with peg-IFN α2a warrants further investigation.